Want to see TSE:TLT full AI Analyst Report?
TLT Stock Chart & Stats
C$0.18
>-C$0.01(-1.89%)
At close: 4:00 PM EDT
C$0.18
>-C$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeC$0.15 - C$0.41
Previous CloseN/A
Volume18.52K
Average Volume (3M)382.65K
Market Cap
C$57.44M
Enterprise ValueC$67.31
Total Cash (Recent Filing)C$5.26M
Total Debt (Recent Filing)C$148.72K
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Dec 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding310,483,300
10 Day Avg. Volume163,098
30 Day Avg. Volume382,651
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)23.49
Price to Sales (P/S)51.16
P/FCF Ratio-12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)C$802.00K
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces refinancing pressure and preserves financial flexibility compared with a highly indebted structure. This gives Theralase more capacity to direct available resources toward device commercialization and pharmaceutical development, although it does not by itself resolve the company’s operating losses.
Improved Gross MarginImproved gross margin indicates better product-level economics than in the prior period and could support future operating leverage if revenue expands. The benefit is durable only if the company can sustain this efficiency while increasing sales enough to absorb its substantial operating cost base.
Dual Technology PlatformTheralase combines medical-device development with photodynamic-therapy drug research, creating two related avenues for long-term product development. Progress in either platform could broaden its commercial opportunity, while the shared focus on light-based therapy provides strategic coherence across the portfolio.
Bears Say
Declining RevenueSmall and declining revenue indicates that the current commercial base is not yet producing dependable scale. Without a sustained return to growth, Theralase may struggle to spread development and operating costs across sales, limiting the company’s ability to convert its technology portfolio into recurring financial strength.
Deep Persistent LossesA deeply negative net margin shows that the present cost structure is far too large for the revenue base, while the history of persistent losses suggests no established path to operating profitability. Continued losses can erode equity and constrain investment in commercialization, clinical work, and future growth.
Sustained Cash BurnMaterially negative operating and free cash flow means the business is not currently self-funding its activities. Cash consumption that is large relative to revenue increases dependence on external funding over time, potentially diluting owners or forcing development and commercialization priorities to be constrained.
Theralase Technologies News
TLT FAQ
What was Theralase Technologies’s price range in the past 12 months?
Theralase Technologies lowest stock price was C$0.14 and its highest was C$0.41 in the past 12 months.
What is Theralase Technologies’s market cap?
Theralase Technologies’s market cap is C$57.44M.
When is Theralase Technologies’s upcoming earnings report date?
Theralase Technologies’s upcoming earnings report date is Dec 02, 2026 which is in 72 days.
How were Theralase Technologies’s earnings last quarter?
Theralase Technologies released its earnings results on Aug 28, 2026. The company reported -C$0.003 earnings per share for the quarter.
Is Theralase Technologies overvalued?
According to Wall Street analysts Theralase Technologies’s price is currently Overvalued.
Does Theralase Technologies pay dividends?
Theralase Technologies does not currently pay dividends.
What is Theralase Technologies’s EPS estimate?
Theralase Technologies’s EPS estimate is >-0.01.
How many shares outstanding does Theralase Technologies have?
Theralase Technologies has 310,483,300 shares outstanding.
What happened to Theralase Technologies’s price movement after its last earnings report?
Theralase Technologies reported an EPS of -C$0.003 in its last earnings report. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Theralase Technologies?
Currently, no hedge funds are holding shares in TSE:TLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theralase Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$25.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
169.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Theralase Technologies
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
Technical Analysis
Aurora Spine
―
―
Perimeter Medical Imaging AI
―
Profound Medical
―
VentriPoint Diagnostics
―